Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Nazbuster who wrote (17872)	3/7/1999 2:18:00 PM
From: Land Shark	Respond to of 122087

I'm sure there's at least 1000 similar OTC BB scam issues like this one out there for under a $1. Unfortunately, I and others can't short 'em.

To: Nazbuster who wrote (17872)	4/18/1999 8:31:00 PM
From: RockyBalboa	Respond to of 122087

Hi, Daniel... Just searched my mailbox and out came a spam of the same content. There is even a thread in SI... STINKY STOCK. Seems to be a long-running chainletter. --------------------------------- From: stock_news4u@netspace.net.au Relay: businesnet@netspace.net.au RE: BIOTECH BARGAIN! Company: Endovasc Ltd., Inc. Symbol: E N D V Price: 9/16 ($.56/share) Whisperstocks indicates persistent and credible rumours of a $4/share buyout of ENDV by a major pharamceutical. The April issue of the British Biotechnology Journal, Oxford, England states "scientists at Glaxo Wellcome have proven the efficacy of Endovasc's PGE-1 and have submitted to management a multi-million dollar joint venture proposal". ENDV is recommended as an immediate and "STRONG BUY". ------------- Brrr, IS